Navigation Links
Amicus Therapeutics Opens Research Facility in San Diego
Date:9/15/2008

CRANBURY, N.J. and SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has leased laboratory space for a focused, small scale research facility in San Diego. The facility will be used to support ongoing research into new applications of the company's platform technology.

"With proof of concept for pharmacological chaperones now established, research at the San Diego facility will support Amicus' efforts to expand our early stage pipeline," said David Lockhart, Ph.D., chief scientific officer for Amicus Therapeutics. "Locating the new laboratory in San Diego allows us to complement and expand our existing research capabilities in Cranbury by tapping into the significant resources and expertise of the San Diego science and biotechnology community."

"We believe pharmacological chaperones have significant potential to treat a broad range of genetic diseases," added John Crowley, president and CEO of Amicus. "The focus of our research efforts in San Diego will be to assess new chaperone applications in diseases with high unmet medical needs and larger patient populations particularly in the areas of neurodegenerative and metabolic disorders. This small scale facility will complement our core research and development activities in New Jersey."

The new laboratory space was included in Amicus' operating plan and budget for 2008 as part of increased investment in research beyond the lysosomal storage disorders. Amicus expects to begin occupying the space immediately.

About Amicus Therapeutics

Amicus Therape
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Chemical Sciences play a significant ... clean air and safe water, healthy food, and ... environmentalists, food scientists, educators, and scientists have a ... field of Chemistry for the national development, and ... of the fastest emerging Sciences, accelerating with a ...
(Date:9/20/2014)... BELLINGHAM, Washington, and PITTSFIELD, Massachusetts, USA (PRWEB) September 20, ... 10 October for the prestigious 2015 Prism Awards ... technology and product inventions from the multi-billion dollar optics ... the international society for optics and photonics , and ... and persistence as well as the versatility of photonics, ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary combined ... the specialized Wolvega Horse Clinic. , Due to a ... ruptured 90% and her deep digital flexor tendon 50%. ... for a horse. , The clinic has performed numerous ... This revolutionary regenerative option for ruptured tendons has only ...
Breaking Biology Technology:Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... Life ... Science Companies, ... Trade Zone (FTZ) Service targeting pharmaceutical and,biotechnology companies engaged in ... and creates significant,financial advantages and supply chain efficiencies for life ...
... Nussberger, MD, Today at 9.45am (EST):, "CYT006-AngQb, a Vaccine Against Hypertension ... Reduces Early-Morning and Day-Time Blood Pressure.", The American Heart Association Publishes Today ... ... Safety and Tolerability Profile Confirmed: no, Vaccine-Related Adverse Events Reported ...
... 6 Centocor,Inc., Schering-Plough Corporation, and Mitsubishi ... one million patients have now been,treated with ... therapy worldwide. In fact, REMICADE has been ... other anti-TNF-alpha agents,combined. REMICADE was the first ...
Cached Biology Technology:Sentry Logistic Solutions Launches Foreign Trade Zone Service 2Sentry Logistic Solutions Launches Foreign Trade Zone Service 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 2Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 4Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 5Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 6Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 2REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 3REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 4REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 5REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 6REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 7REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 8REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 9REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 10REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 11REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide 12
(Date:9/18/2014)... how many times it,s demonstrated, it,s still hard ... , But by using a signaling system called ... behavior to suit their population. In short, some ... and act accordingly. , Once the population of ... from innocuous to pathogenic, or from unhelpful to ...
(Date:9/18/2014)... in DNA, tiny strands of nucleic acid that contain ... this genetic data, our DNA is copied into RNA ... perform tasks in our cells. , Several years ... Unlike all other known RNAs, this molecule is circular, ... abundant, little has been known about how they are ...
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Visualized Experiments) , the revolutionary scientific journal that pairs ... to announce that submissions are now open for ... This new section will enable scientists studying behavior ... video format, bringing this scientific field to new levels ...
... A team of researchers at The New York ... PhD, Director of the NYSCF Laboratory and the NYSCF ... and Michael W. Nestor, PhD, a NYSCF Postdoctoral Research ... of induced pluripotent stem (iPS) cells called embryoid bodies, ...
... Md. (April 1, 2013)Almost four million people die each year ... combustion of biomass fuels (wood, charcoal, crop residues, and dung), ... millions who rely on such products to cook their meals, ... and middle income countries are among the hardest hit by ...
Cached Biology News:NYSCF scientists develop 3-D stem cell culture technique to better understand Alzheimer's disease 2Deadly effects of certain kinds of household air pollution lead to call for biomarker studies 2Deadly effects of certain kinds of household air pollution lead to call for biomarker studies 3
Automated Cell Culture Flask...
Cell Culture Flask, 75 cm, treated polystyrene...
... style shaker flasks have three extra deep ... solutions to improve oxygen or gas transfer ... The long neck reduces splashing and is ... wall thickness provides the proper balance between ...
... IS System is a compact analysis system for ... optics, fluidics, a controller, advanced digital signal processing ... lab analysis system includes the Luminex 100, the ... a DMF file at the FDA, and partner ...
Biology Products: